TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions

Giandomenico Roviello; Alberto D'Angelo; Marianna Sciortino; Enrico Mini; Stefania Nobili; Francesco De Logu; Daniela Massi

doi:10.1016/j.critrevonc.2020.103011

TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions

Giandomenico Roviello
, Alberto D'Angelo
, Marianna Sciortino
, Enrico Mini
, Stefania Nobili
, Francesco De Logu
, Daniela Massi

Department of Life Sciences

AstraZeneca, Cambridge
Sasol Technology (UK) Ltd
University of Florence
Careggi University Hospital

Research output: Contribution to journal › Review article › peer-review

17 Citations (SciVal)

207 Downloads (Pure)

Abstract

Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of "tumour-agnostic" targeted therapies in rare malignancies.

Original language	English
Article number	103011
Journal	Critical Reviews in Oncology/Hematology
Volume	152
Early online date	31 May 2020
DOIs	https://doi.org/10.1016/j.critrevonc.2020.103011
Publication status	Published - 31 Aug 2020

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.critrevonc.2020.103011

1_s2.0_S1040842820301499_mainAccepted author manuscript, 649 KBLicence: CC BY-NC-ND

Cite this

@article{501229ba931a4b0296b27983af5c49e9,

title = "TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions",

abstract = "Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel {"}basket{"} study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of {"}tumour-agnostic{"} targeted therapies in rare malignancies.",

author = "Giandomenico Roviello and Alberto D'Angelo and Marianna Sciortino and Enrico Mini and Stefania Nobili and \{De Logu\}, Francesco and Daniela Massi",

year = "2020",

month = aug,

day = "31",

doi = "10.1016/j.critrevonc.2020.103011",

language = "English",

volume = "152",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - TRK fusion positive cancers

T2 - From first clinical data of a TRK inhibitor to future directions

AU - Roviello, Giandomenico

AU - D'Angelo, Alberto

AU - Sciortino, Marianna

AU - Mini, Enrico

AU - Nobili, Stefania

AU - De Logu, Francesco

AU - Massi, Daniela

PY - 2020/8/31

Y1 - 2020/8/31

N2 - Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of "tumour-agnostic" targeted therapies in rare malignancies.

AB - Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. In this review, we focus on the challenges and expectations on the development of "tumour-agnostic" targeted therapies in rare malignancies.

U2 - 10.1016/j.critrevonc.2020.103011

DO - 10.1016/j.critrevonc.2020.103011

M3 - Review article

C2 - 32521311

SN - 1040-8428

VL - 152

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 103011

ER -

TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this